---
title: "post-transplant_maintenance_therapy"
slug: "post-transplantmaintenancetherapy"
date: "2024-05-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[hematopoietic stem cell transplantation]]

# post-transplant_maintenance_therapy

- Lenalidomide
  - maintenance improves PFS & OS for MM (JCO 2016 [suppl; abstr 8001]; NEJM 2014;371:895)
- Rituximab
  - maintenance showed no benefit for DLBCL based on randomized phase III data
    - ([[coral.md|CORAL]] study, JCO 2010;28:4184), but showed PFS benefit in FL (EBMT LYM1 study, JCO 2013;31:1624) & PFS & OS benefit in MCL (particularly in younger pts) (NEJM 2017;377:1250)
- BV
  - maintenance in 1Â° refractory or unfav relapsed HL pts not previously exposed to BV showed PFS benefit in a randomized phase III study ([[aethera.md|AETHERA]], Lancet 2015;385:1853)
